GBLP
Global Pharmatech, Inc. engages in the research, production, and development of herbal medicine, bio-medicine, chemical medicine, traditional chinese medicine, and dietary supplements primarily in China. The company's principal product line consists of XS CAPSULE (XIN-SHU) for the treatment of angina and other coronary disease; JUTAI SOFT CAPSULE, a dietary supplement; QINGXUAN ANTI-HYPERTENSION TABLET, an over-the-counter drug product indicated for the treatment of hypertension and high serum cholesterol level; and YANREQING TABLET for the treatment of inflammation. It also manufactures and sells other proprietary drugs, generics, and dietary supplements used to treat symptoms ranging from headaches, coughing, and dry mouth to infections, and numbness of limbs. The company markets its products through distributors, such as wholesale companies and chain store representatives, as well as through its sales force. Global Pharmatech, Inc. was founded in 2001 and is based in Changchun, China.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.00 | $328,189 | -$79,940 |
| 2025 Q2 | 0.00 | $32,400 | $0 |
| 2025 Q1 | 0.00 | $24,709 | $0 |
| 2024 Q4 | -0.00 | $25,934 | $0 |
| 2024 Q3 | 0.00 | $144,654 | $0 |
| 2024 Q2 | -0.00 | $113,456 | $0 |
| 2024 Q1 | 0.00 | $26,850 | -$16,789 |
| 2023 Q4 | -0.00 | $36,875 | -$32,215 |